High-Dose Simvastatin as a Potential Trigger for Angioedema: A Case Report for Broader Diagnostic Consideration

Abstract

Angioedema (AE) is a potentially life-threatening condition involving swelling under the skin. The most common pharmacologic cause of this reaction is angiotensin-converting enzyme (ACE) inhibitor (ACEi) therapy, but other medications may contribute to the development of AE. This case describes a 68-year-old male who presented to the emergency department with tongue and lip swelling and was diagnosed with AE, initially attributed to lisinopril use. However, outpatient follow-up revealed that the only recent medication change was an inadvertent supratherapeutic 60 mg daily dose of simvastatin. Furthermore, the patient was found to have a medical history of AE secondary to atorvastatin use 13 years prior. Based on his history, the ACEi was discontinued, and the statin dose was reduced with symptom resolution. The patient’s clinical course adds to the limited literature on statin-induced AE, particularly in the setting of concurrent ACEi use. It also underscores the importance of thorough medication reconciliation and avoiding premature diagnoses of the most common etiology.

Introduction

Angioedema (AE) is a transient, nonpitting swelling of the deeper layers of the skin or mucosa, most commonly involving the face, lips, tongue, and airway. Involvement of the upper airway can lead to airway obstruction and potentially respiratory failure and death. It is often mediated by elevated histamine or bradykinin, which leads to increased vascular permeability and swelling. ¹ The most common cause of medication-induced AE is angiotensin-converting enzyme inhibitor (ACEi) therapy through reduced degradation of bradykinin and substance P. ACEi-AE accounts for approximately one-third of all AE presentations, occurring in 0.1% to 0.7% of patients on ACEi.^1,2 The reaction is not always immediate, but most cases occur within the first year of therapy. ³

While the association between ACEi and AE is well established, less is known about other pharmacologic agents that may influence the risk of AE. As a result, clinicians may overlook alternative or concurrent causes. This case report aims to demonstrate an instance of AE likely secondary to statin therapy. Statins are more commonly associated with myopathy, a side effect seen in ~10% to 15% of patients taking the medication. ⁴ A few case reports have linked AE to statin use in patients on isolated statin therapy or while taking non-ACEi medications.^5-7 However, statin-induced AE in the presence of concurrent ACEi use is widely unreported.

Our case adds to the body of literature by highlighting a patient with presumed ACEi-induced AE after inadvertently taking a supratherapeutic dose of simvastatin, emphasizing the need for broader differentials and thorough medication reconciliation.

Case Presentation

Written informed consent for publication of the case details was obtained from the patient. Clinical data were collected from the patient’s medical records, including presenting symptoms, diagnostic workup, treatment interventions, and follow-up outcomes. Health records were requested regarding 2 emergency department visits related to the case; however, only the records from the recent visit were available. Records from the visit 13 years prior could not be obtained.

A 68-year-old male patient presented to the emergency department with tongue and lip swelling without associated urticaria. A computed tomography scan with contrast of the maxillofacial region demonstrated mild-to-moderate soft tissue swelling of the dorsum of the tongue, filling the anterior oropharynx, without evidence of intrinsic mass, gas, contrast enhancement, or fluid collection. He was diagnosed with AE secondary to ACEi use, specifically lisinopril. The patient was treated with intravenous dexamethasone and diphenhydramine, and his symptoms resolved. He was discharged the next day with instructions to hold all medications and follow up with his primary care provider.

Two days after being seen in the emergency department, the patient presented for outpatient follow-up. A thorough history revealed that the lisinopril in question had been initiated ~28 months prior without any changes in dose, decreasing suspicion for ACEi-AE. It was also discovered that the patient was taking simvastatin, initiated at the same time as the lisinopril, but his dose had recently been increased from 20 to 40 mg a little over a month prior due to poor lipid control. An attempt had been made to switch the patient to rosuvastatin instead, but the change was not approved by his insurance. After receiving the higher-dose prescription, the patient admitted he had gotten confused and had been taking both his previous simvastatin prescription (20 mg) and his newly prescribed dose (40 mg) simultaneously, resulting in a total daily dose of 60 mg for over a month. He also disclosed a previous episode of AE ~13 years ago that required hospitalization and emergent tracheostomy. This previous admission was attributed to atorvastatin use, as he was not on ACEi therapy at the time. Given his medical history of atorvastatin-related AE, there was concern that his more recent episode might have been caused by the acute 200% increase in simvastatin dose. His simvastatin prescription was lowered back to 20 mg daily, and he was prescribed an epinephrine autoinjector for emergency use. The patient’s lisinopril was replaced with losartan 25 mg, to be initiated only if no adverse reaction occurred after trial of the lower simvastatin dose. A subsequent visit was scheduled for 2 weeks to reassess medication tolerance and guide future management.

The patient returned 2 weeks later for assessment of his new medical regimen. He reported taking the simvastatin 20 mg along with losartan 25 mg and denied any complications, including facial swelling. He was advised to continue this regimen with close follow-up for possible future adjustments. A summary of the patient’s clinical course is shown in Figure 1.

Figure 1.

Timeline of events relative to the index emergency department visit (day 0), showing prior statin and ACE inhibitor exposure, presentation with angioedema, and resolution after medication adjustment. ACE, angiotensin-converting enzyme.

Discussion

This case describes a patient diagnosed with AE while taking a supratherapeutic dose of simvastatin and a stable dose of lisinopril. The episode was attributed to ACEi therapy despite: (1) documented use of lisinopril for over 2 years without adverse effects, (2) history of atorvastatin-induced AE, and (3) recent inadvertent 3-fold increase of simvastatin. The acute increase in simvastatin dose preceded the onset of AE in this patient by ~1 month, and the absence of prior episodes on the lower dose suggests a possible dose-dependent interaction. While the influence of lisinopril cannot be completely ignored, these factors should have raised suspicion for an alternative or at least contributory trigger beyond ACEi therapy alone. Over-reliance on the association between ACEi and AE risks, overlooking other potential causes. It is possible that other cases of AE may be inappropriately attributed solely to ACEi use, ignoring the role statins may play.

The pharmacodynamics of these drugs may explain this interaction. While ACEi elevate bradykinin levels, statins may enhance tissue sensitivity to bradykinin via receptor modulation, such as upregulating bradykinin B2 receptors or altering endothelial nitric oxide synthase pathways. ⁸ When combined, the additive or synergistic effects may amplify their vasodilatory and permeability mechanisms. However, whether statins meaningfully alter bradykinin responsiveness in vivo is uncertain; evidence is limited and largely nonclinical, so any mechanistic interaction should be viewed as speculative. In contrast, it is possible that statin-induced AE simply reflects a hypersensitivity reaction with no association with ACEi therapy. Thus, further pharmacological studies are warranted to better assess the relationship between these medications.

While statin-induced AE is rare, a few isolated case reports have been documented, but these cases did not involve patients who were concurrently on ACEi therapy.^5-7 Al-Qaaneh et al reported AE in a patient taking losartan and amlodipine, triggered by an atorvastatin dose increase from 20 to 40 mg. ⁵ This patient mirrored our case of statin dose increase with concurrent use of bradykinin-modulating agents, but the diagnosis was not obscured by concurrent ACEi therapy. Similarly, Ben Belgacem et al described a case series of 4 patients who experienced AE after statin initiation or dose increase, among whom none were documented as taking ACEi. ⁶ Additionally, Kumar et al reported a case of fluvastatin-induced tongue AE that resolved with tranexamic acid, also in the absence of ACEi use. ⁷ It is plausible that the frequency of statin-induced AE may be more common than otherwise thought; however, concurrent ACEi use may potentiate this risk and obscure attribution to statin therapy.

While ACEi have many effective alternatives for blood pressure control, statins lack equally effective alternatives for lipid control and cardiovascular risk reduction. Statins are first-line for LDL cholesterol reduction, and meta-analyses demonstrate that each 1.0 mmol/L (39 mg/dL) reduction in LDL cholesterol lowers the risk of vascular events by over 20%. ⁹ Given the high morbidity and mortality associated with cardiovascular disease, patients experiencing statin-induced AE may still tolerate low-dose or low-potency statin therapy as demonstrated in our case. Substituting medications such as ACEi with lower-risk alternatives like angiotensin receptor blockers (ARBs) may improve statin tolerability and permit higher doses. While ARBs can also precipitate AE, the risk has been estimated to be only one-third the risk in ACEi.^10,11

There are several limitations to this study. As a single-patient case report, causality cannot be confirmed. Statin rechallenge was performed only to 20 mg and for only 2 weeks, and prior records from the atorvastatin-associated AE event were unavailable. Nevertheless, the temporal association between statin overdose and symptom onset strengthens the suspicion of statin involvement. Future studies, including retrospective reviews comparing the incidence of AE in patients on combined ACEi-statin therapy versus either agent alone, are warranted to better characterize the potential contribution of statins to AE risk.

Conclusion

This case emphasizes the importance of considering statins, particularly at high doses or concurrently with ACEi, as potential contributors to AE. Medication dosing and interactions often shift risk profiles, underscoring the importance of maintaining broad differentials without diagnostic anchoring. Comprehensive medication reconciliation and individualized therapy adjustments are essential to balancing medication benefits with more obscure side effects.